Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI, Sagara Y, Yotsumoto D, Kanemitsu S, Kawano J, Baba S, Rai Y, Oshiro Y, Aogi K, Sagara Y, Ohi Y. Hida AI, et al. Among authors: aogi k. Breast Cancer Res Treat. 2016 Jul;158(1):1-9. doi: 10.1007/s10549-016-3848-2. Epub 2016 Jun 3. Breast Cancer Res Treat. 2016. PMID: 27260189 Free PMC article.
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.
Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M. Barrios CH, et al. Among authors: aogi k. Breast Cancer Res Treat. 2010 May;121(1):121-31. doi: 10.1007/s10549-010-0788-0. Epub 2010 Mar 26. Breast Cancer Res Treat. 2010. PMID: 20339913 Free PMC article. Clinical Trial.
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype.
Aogi K, Yoshida M, Sagara Y, Kamigaki S, Okazaki M, Funai J, Fujimoto T, Toi M, Saeki T, Takashima S. Aogi K, et al. Cancer Chemother Pharmacol. 2011 May;67(5):1007-15. doi: 10.1007/s00280-010-1390-1. Epub 2010 Jul 14. Cancer Chemother Pharmacol. 2011. PMID: 20628744 Clinical Trial.
Detection of isolated ipsilateral regional lymph node recurrences by F18-fluorodeoxyglucose positron emission tomography-CT in follow-up of postoperative breast cancer patients.
Ohsumi S, Inoue T, Kiyoto S, Hara F, Takahashi M, Takabatake D, Takashima S, Aogi K, Takashima S. Ohsumi S, et al. Among authors: aogi k. Breast Cancer Res Treat. 2011 Nov;130(1):267-72. doi: 10.1007/s10549-011-1561-8. Epub 2011 May 13. Breast Cancer Res Treat. 2011. PMID: 21590272
229 results